Business
European patent for AppDx® smartphone reader
Abingdon Health plc has announced the granting of a new European patent, EP4150565, for its AppDx® lateral flow smartphone reader, following recent patent grants in the USA and UK. This AppDx® technology is a software development kit that utilizes smartphone cameras and deep learning algorithms to read colorimetric lateral-flow tests, enabling qualitative and semi-quantitative results. The company views this as a valuable tool for its contract development and manufacturing customers, highlighting ongoing innovation in the lateral flow market. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n \nAbingdon Health plc\n(\"Abingdon Health\" or \"the Company\")\n \nEuropean patent for AppDx® lateral flow smartphone reader\n \nYork, U.K. 18 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the granting of an additional patent for its AppDx® lateral flow smartphone reader.\n \nThe new European patent \"Assay Reading Method\" with patent number EP4150565 has been granted and follows the recent granting of a similar patent in USA with patent number US 12,373,946 B2, with other patents already granted in UK.\n \n\n \n \nAppDx® is a software development kit for reading colorimetric lateral-flow tests organized for Android™ and iOS® smartphone operating systems. AppDx® enables lateral-flow test readout from your pocket, enabled by a smartphone camera. It consists of a software application programming interface accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms are customized and tuned for each test. The Abingdon Health AppDx® algorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low).\n \nDr Chris Hand, Executive Chairman of Abingdon Health plc, commented:\n\"We are pleased to announce the granting of a further patent for our AppDx® lateral flow smartphone lateral flow reader. This is another tool available to our contract development and manufacturing customers and illustrates the continued innovation in the lateral flow market.\"\n \nEnquiries:\n \n\n\n\n\nAbingdon Health plc\n\n\nwww.abingdonhealth.com/investors/\n\n\n\n\nChris Hand, Executive Chairman\n \n\n\nVia Walbrook PR\n\n\n\n\nTom Hayes, CFO\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Media & Investor Relations)\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n \n\n \nAbout Abingdon Health\n \nAbingdon Health Group is a leading med-tech contract service provider offering its services to an international customer ...